An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 21 Oct 2017 Planned number of patients changed from 150 to 85.
- 19 May 2017 Status changed from planning to recruiting.
- 23 Sep 2016 New trial record